MA55021A - 5-méthoxy-n,n-diméthyltryptamine (5-méo-dmt) pour la traitement de la dépression - Google Patents
5-méthoxy-n,n-diméthyltryptamine (5-méo-dmt) pour la traitement de la dépressionInfo
- Publication number
- MA55021A MA55021A MA055021A MA55021A MA55021A MA 55021 A MA55021 A MA 55021A MA 055021 A MA055021 A MA 055021A MA 55021 A MA55021 A MA 55021A MA 55021 A MA55021 A MA 55021A
- Authority
- MA
- Morocco
- Prior art keywords
- dimethyltryptamine
- dmt
- meo
- depression
- methoxy
- Prior art date
Links
- ZSTKHSQDNIGFLM-UHFFFAOYSA-N 5-methoxy-N,N-dimethyltryptamine Chemical compound COC1=CC=C2NC=C(CCN(C)C)C2=C1 ZSTKHSQDNIGFLM-UHFFFAOYSA-N 0.000 title 4
- 208000020401 Depressive disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19158774 | 2019-02-22 | ||
PCT/EP2020/054803 WO2020169850A1 (fr) | 2019-02-22 | 2020-02-24 | 5-méthoxy-n,n-diméthyltryptamine (5-méo-dmt) pour la traitement de la dépression |
Publications (2)
Publication Number | Publication Date |
---|---|
MA55021A true MA55021A (fr) | 2021-12-29 |
MA55021B1 MA55021B1 (fr) | 2024-05-31 |
Family
ID=65529503
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA55021A MA55021B1 (fr) | 2019-02-22 | 2020-02-24 | 5-methoxy-n,n-dimethyltryptamine (5-meo-dmt) pour le traitement de la depression majeure |
Country Status (30)
Country | Link |
---|---|
US (2) | US20220071958A1 (fr) |
EP (3) | EP4353314A3 (fr) |
JP (1) | JP2022521337A (fr) |
KR (1) | KR20210154966A (fr) |
CN (1) | CN114555078A (fr) |
AU (1) | AU2020225410A1 (fr) |
BR (1) | BR112021016153A2 (fr) |
CA (1) | CA3130406A1 (fr) |
CL (1) | CL2021002174A1 (fr) |
CO (1) | CO2021010882A2 (fr) |
CR (1) | CR20210437A (fr) |
DK (1) | DK3927337T3 (fr) |
DO (1) | DOP2021000176A (fr) |
EA (1) | EA202192318A1 (fr) |
EC (1) | ECSP21060868A (fr) |
FI (1) | FI3927337T3 (fr) |
HR (1) | HRP20240532T1 (fr) |
HU (1) | HUE066828T2 (fr) |
IL (1) | IL285537A (fr) |
LT (1) | LT3927337T (fr) |
MA (1) | MA55021B1 (fr) |
MD (1) | MD3927337T2 (fr) |
MX (1) | MX2021009941A (fr) |
NI (1) | NI202100080A (fr) |
PE (1) | PE20220015A1 (fr) |
PL (1) | PL3927337T3 (fr) |
PT (1) | PT3927337T (fr) |
RS (1) | RS65706B1 (fr) |
SI (1) | SI3927337T1 (fr) |
WO (1) | WO2020169850A1 (fr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT3927337T (lt) | 2019-02-22 | 2024-07-10 | GH Research Ireland Limited | 5-metoksi-n,n-dimetiltriptaminas (5-meo-dmt), skirtas didžiosios depresijos sutrikimo gydymui |
GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
EP3753923A1 (fr) * | 2019-06-19 | 2020-12-23 | GH Research Limited | Récrystallisation de 5-méthoxy-n,n-diméthyltryptamine (5-meo-dmt) dans de méthyl tert.-butyl éther (mtbe) sans ajouter un antisolvant |
CN114829341B (zh) | 2019-11-07 | 2024-03-08 | 赛本英国有限公司 | 合成方法 |
EP3868364A1 (fr) * | 2020-02-24 | 2021-08-25 | GH Research Limited | Aérosol comrpenant 5-methoxy-n,n-dimethyltryptamine |
EP4397371A2 (fr) | 2020-05-19 | 2024-07-10 | Cybin IRL Limited | Dérivés de tryptamine deutérés et procédés d'utilisation |
US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
EP3941904A1 (fr) | 2020-06-12 | 2022-01-26 | Beckley Psytech Limited | Composition pharmaceutique comprenant de la 5-méthoxy-n, n-diméthyltryptamine |
JP7567024B2 (ja) * | 2020-08-05 | 2024-10-15 | ユニヴェルシテートスピタル バーゼル | Dmt補助心理療法のための静脈内dmt投与方法 |
US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
EP4138818B1 (fr) * | 2020-08-28 | 2024-08-21 | Cybin UK Ltd | Formulation injectable |
WO2022069690A2 (fr) * | 2020-10-02 | 2022-04-07 | Cybin Irl Limited | Méthodes d'administration de médicaments psychédéliques par inhalation et systèmes de mise en œuvre des méthodes |
CN112138028A (zh) * | 2020-10-10 | 2020-12-29 | 南京中医药大学 | 蟾蜍色胺类物质在制备抗抑郁药物中的应用 |
WO2022082058A1 (fr) * | 2020-10-16 | 2022-04-21 | Eleusis Therapeutics Us, Inc. | Méthode de traitement par alcaloïdes tryptamines |
EP4255421A1 (fr) * | 2020-12-01 | 2023-10-11 | Small Pharma Ltd | Formulations inhalables |
US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
CA3113414A1 (fr) * | 2021-03-29 | 2022-09-29 | Mind Cure Health Inc. | Protocole psychedelique pour systemes et methodes informatiques |
BR112023022195A2 (pt) | 2021-04-26 | 2024-01-16 | Atai Therapeutics Inc | Novas composições e métodos de n,n-dimetiltriptamina |
US20240246911A1 (en) * | 2021-05-05 | 2024-07-25 | Gilgamesh Pharmaceuticals | Novel tryptamines and methods of treating mood disorders |
JP2024522174A (ja) | 2021-06-09 | 2024-06-11 | アタイ セラピューティクス, インコーポレイテッド | ジメチルトリプタミンの新規プロドラッグおよびコンジュゲート |
US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
EP4159201A1 (fr) * | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Nanoparticules encapsulées et nanoparticules de diméthyltriptamines |
WO2023089132A1 (fr) * | 2021-11-18 | 2023-05-25 | Small Pharma Ltd | Formulations injectables et inhalables |
WO2023129956A2 (fr) | 2021-12-30 | 2023-07-06 | ATAI Life Sciences AG | Analogues de diméthyltryptamine utilisés en tant que médicaments d'administration d'oxyde nitrique |
US12060328B2 (en) | 2022-03-04 | 2024-08-13 | Reset Pharmaceuticals, Inc. | Co-crystals or salts of psilocybin and methods of treatment therewith |
WO2023186824A1 (fr) | 2022-03-27 | 2023-10-05 | GH Research Ireland Limited | 5-méthoxy-n,n-diméthyltryptamine pour le traitement d'un dysfonctionnement cognitif |
WO2023186835A1 (fr) | 2022-03-27 | 2023-10-05 | GH Research Ireland Limited | Traitement de troubles mentaux |
WO2023186834A1 (fr) | 2022-03-27 | 2023-10-05 | GH Research Ireland Limited | Sel de bromhydrate cristallin de 5-meo-dmt |
GB202212116D0 (en) | 2022-08-19 | 2022-10-05 | Beckley Psytech Ltd | Pharmaceutically acceptable salts and Compositions thereof |
WO2024160390A1 (fr) | 2023-01-30 | 2024-08-08 | GH Research Ireland Limited | 5-méthoxy-n,n-diméthyltryptamine pour le traitement de la dépression post-partum |
WO2024160391A1 (fr) | 2023-01-30 | 2024-08-08 | GH Research Ireland Limited | Traitement de troubles mentaux |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19803376C1 (de) | 1998-01-29 | 1999-10-14 | Markus Storz | Inhalator zur Erzeugung von aroma- und/oder wirkstoffhaltigen Dämpfen aus Pflanzenmaterial und/oder Flüssigkeiten |
US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
US20030051728A1 (en) | 2001-06-05 | 2003-03-20 | Lloyd Peter M. | Method and device for delivering a physiologically active compound |
CA2526475A1 (fr) | 2003-05-21 | 2004-12-02 | Alexza Pharmaceuticals, Inc. | Unite de chauffage autonome a allumage optique ou electrique, et unite d'administration de medicament utilisant cette unite de chauffage |
EP1884254B8 (fr) | 2006-08-01 | 2011-02-23 | Stobi GmbH & Co. KG | Ballon à valve pour inhalateurs |
CN103816150A (zh) * | 2014-03-14 | 2014-05-28 | 兰州理工大学 | 山蚂蝗生物碱单体成分的用途 |
WO2018195455A1 (fr) * | 2017-04-20 | 2018-10-25 | Eleusis Benefit Corporation, Pbc | Évaluation et traitement de sujets réactifs aux agents psychédéliques |
WO2019081764A1 (fr) * | 2017-10-26 | 2019-05-02 | Consejo Superior De Investigaciones Científicas (Csic) | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques |
LT3927337T (lt) | 2019-02-22 | 2024-07-10 | GH Research Ireland Limited | 5-metoksi-n,n-dimetiltriptaminas (5-meo-dmt), skirtas didžiosios depresijos sutrikimo gydymui |
-
2020
- 2020-02-24 LT LTEPPCT/EP2020/054803T patent/LT3927337T/lt unknown
- 2020-02-24 SI SI202030414T patent/SI3927337T1/sl unknown
- 2020-02-24 EP EP24157388.0A patent/EP4353314A3/fr active Pending
- 2020-02-24 EA EA202192318A patent/EA202192318A1/ru unknown
- 2020-02-24 CR CR20210437A patent/CR20210437A/es unknown
- 2020-02-24 WO PCT/EP2020/054803 patent/WO2020169850A1/fr active Application Filing
- 2020-02-24 PE PE2021001360A patent/PE20220015A1/es unknown
- 2020-02-24 FI FIEP20710059.5T patent/FI3927337T3/fi active
- 2020-02-24 MD MDE20211248T patent/MD3927337T2/ro unknown
- 2020-02-24 CA CA3130406A patent/CA3130406A1/fr active Pending
- 2020-02-24 RS RS20240531A patent/RS65706B1/sr unknown
- 2020-02-24 EP EP20710059.5A patent/EP3927337B8/fr active Active
- 2020-02-24 HU HUE20710059A patent/HUE066828T2/hu unknown
- 2020-02-24 KR KR1020217030215A patent/KR20210154966A/ko unknown
- 2020-02-24 CN CN202080030317.3A patent/CN114555078A/zh active Pending
- 2020-02-24 PL PL20710059.5T patent/PL3927337T3/pl unknown
- 2020-02-24 US US17/431,626 patent/US20220071958A1/en not_active Abandoned
- 2020-02-24 DK DK20710059.5T patent/DK3927337T3/da active
- 2020-02-24 EP EP24157425.0A patent/EP4349407A3/fr active Pending
- 2020-02-24 JP JP2021549427A patent/JP2022521337A/ja active Pending
- 2020-02-24 BR BR112021016153-8A patent/BR112021016153A2/pt unknown
- 2020-02-24 MX MX2021009941A patent/MX2021009941A/es unknown
- 2020-02-24 AU AU2020225410A patent/AU2020225410A1/en active Pending
- 2020-02-24 PT PT207100595T patent/PT3927337T/pt unknown
- 2020-02-24 HR HRP20240532TT patent/HRP20240532T1/hr unknown
- 2020-02-24 MA MA55021A patent/MA55021B1/fr unknown
-
2021
- 2021-08-11 IL IL285537A patent/IL285537A/en unknown
- 2021-08-16 CL CL2021002174A patent/CL2021002174A1/es unknown
- 2021-08-17 EC ECSENADI202160868A patent/ECSP21060868A/es unknown
- 2021-08-18 CO CONC2021/0010882A patent/CO2021010882A2/es unknown
- 2021-08-20 DO DO2021000176A patent/DOP2021000176A/es unknown
- 2021-08-20 NI NI202100080A patent/NI202100080A/es unknown
-
2024
- 2024-05-28 US US18/675,614 patent/US20240307350A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA55021A (fr) | 5-méthoxy-n,n-diméthyltryptamine (5-méo-dmt) pour la traitement de la dépression | |
MA47719A (fr) | Esketamine pour le traitement de la dépression | |
MA50578A (fr) | Systèmes crispr/cas pour le traitement de dmd | |
MA55022A (fr) | Compositions comprenant de la 5-méthoxy-n,n-diméthyltryptamine (5-meo-dmt) pour une utilisation dans le traitement de troubles mentaux | |
MA51739A (fr) | Compositions pharmaceutiques pour le traitement de la fibrose kystique | |
MA51139A (fr) | Dérivés de 1-(pipéridinocarbonylméthyl)-2-oxopipérazine pour le traitement du cancer | |
MA51418A (fr) | Inhibiteurs de glycolate oxydase pour le traitement de maladies | |
MA46963A (fr) | Méthodes pour déterminer le dosage de céllules car-t | |
MA55218A (fr) | Eskétamine pour le traitement de la dépression | |
MA42999A (fr) | Polythérapie pour le traitement de malignités | |
MA43800A (fr) | Octréotide par voie orale pour le traitement de maladies | |
MA53501A (fr) | Inhibiteurs de pde9 pour le traitement de la drépanocytose | |
MA50801A (fr) | Polynucléotides codant pour la phénylalanine hydroxylase pour le traitement de la phénylcétonurie | |
MA48791A (fr) | Combinaisons pharmaceutiques de zonisamide et de praxipexole, et procédés associés, pour le traitement de synucléinopathies | |
MA42419A (fr) | Méthode de traitement de l'encéphalopathie hépatique | |
MA55531A (fr) | Procédés pour le traitement de béta-thalassémie | |
MA49375A (fr) | Composition pour le traitement de la blépharite | |
MA41544A (fr) | Dosages de panobinostat pour le traitement du myélome multiple | |
FR3036620B1 (fr) | Utilisation de 3-desoxyanthocyanidines pour le traitement de maladies oculaires | |
MA40065A (fr) | N, n-bis-2-mercaptoéthyle isophtalamide pour le traitement de la maladie de parkinson | |
AU2023244453A1 (en) | 5-methoxy-n,n-dimethyltryptamine for the treatment of anxiety | |
FR3025808B1 (fr) | Systeme de traitement sous vide configure pour deposer au moins un revetement fonctionnel sur une lentille ophtalmique | |
DK3691688T3 (da) | Hydrogelsammensætninger til behandling af molluscum contagiosum | |
UA40088S (uk) | Сепаратор жиру для очищення стічних вод | |
MA54941A (fr) | Polythérapie pour le traitement de malignités des cellules b |